Provided is a therapeutic agent for diseases associated with a cholinergic property of the central nervous system (CNS) and / or the peripheral nervous system (PNS), diseases associated with the contraction of smooth muscle, incretion disease, diseases associated with neuronal degeneration and the like, said therapeutic agent comprising a compound represented by Formula (I):[wherein X-Y-Z represents N-CO-NR4AR4B or the like； R1 represents a phenyl group or the like； R2A and R2B may be the same as or different from each other and independently represent a hydrogen atom or the like； R3A to R3D and R6 may be the same as or different from one another and independently represent a hydrogen atom or the like； R4A and R4B may be the same as or different from each other and independently represent an aryl group or the like； and n represents 1 or 2]or a pharmaceutically acceptable salt thereof and having a potent activity of regulating an α7 nicotinic acetylcholine receptor (an α7 nAChR).
